Live Feeds
โ— TRACKER Updated 28d ago ยท 25 sources tracked

Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data

Foghorn Therapeutics discontinued development of an experimental cancer drug after a partnership with Eli Lilly collapsed due to insufficient benefit in an early-stage trial. The company reduced its workforce by roughly 40 percent, leaving approximately 65 employees. Following the failure of Phase 1 clinical data for the drug FHD-909, Foghorn stock fell over 30 percent, causing its market capitalization to drop below its cash holdings. Pomerantz LLP is currently investigating the firm and its executives for potential securities fraud related to the partnership's failure.

๐ŸŽ™๏ธ

Listen to Live Briefing

Real-time synthesized voice briefing ยท Live Feeds Desk

โฑ ~3 min
Speed:
RSS Source map (25)
โšก Key Developments & Real-Time Context
Text size:
  • โœ“ Foghorn Therapeutics discontinued development of an experimental cancer drug partnered with Eli Lilly.
  • โœ“ Pomerantz LLP is investigating claims of securities fraud against Foghorn Therapeutics and its executives.
  • โœ“ Foghorn reduced its staff to about 65 employees, representing a cut of roughly 40 percent.
  • โœ“ Foghorn stock declined by more than 30 percent.
๐Ÿ›ก๏ธ Source Corroboration: 25 independent reporting domains (90% confidence) โฑ Read time: ~2 min

What changed

Foghorn officially confirmed the discontinuation of the experimental cancer drug development.

Live updates

  1. Foghorn Therapeutics cuts 40% of staff after Eli Lilly collaboration ends

    Foghorn Therapeutics discontinued development of an experimental cancer drug after a partnership with Eli Lilly collapsed due to insufficient benefit in an early-stage trial. The company reduced its workforce by roughly 40 percent, leaving approximately 65 employees. Following the failure of Phase 1 clinical data for the drug FHD-909, Foghorn stock fell over 30 percent, causing its market capitalization to drop below its cash holdings. Pomerantz LLP is currently investigating the firm and its executives for potential securities fraud related to the partnership's failure.

    Why it matters

    The collaboration focused on a selective SMARCA2 degrader program. Such partnerships are critical for small biotech firms to fund research and access pharmaceutical scale. The failure of a lead candidate often triggers drastic cost-cutting measures to preserve remaining capital.

    What is confirmed

    • Foghorn Therapeutics discontinued development of an experimental cancer drug partnered with Eli Lilly.
    • Pomerantz LLP is investigating claims of securities fraud against Foghorn Therapeutics and its executives.
    • Foghorn reduced its staff to about 65 employees, representing a cut of roughly 40 percent.
    • Foghorn stock declined by more than 30 percent.

    Still unconfirmed

    • Phase 1 clinical data for the drug FHD-909 failed to show required efficacy.
    • Eli Lilly terminated the selective SMARCA2 degrader program.
    • Foghorn's market capitalization fell below its cash holdings.

    What to watch next

    • Results of the Pomerantz LLP securities fraud investigation
    • Updates on Foghorn's remaining pipeline assets
    • Further workforce reductions or restructuring announcements
    Sources used for this update (4)
    1. www.cafepharma.com โ€” Eli Lilly | Cafepharma
    2. www.prnewswire.com โ€” INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ...
    3. economictimes.indiatimes.com โ€” eli lilly layoff news News and Updates from The Economic ...
    4. www.marketbeat.com โ€” FHTX News Today | Why did Foghorn Therapeutics stock go down ...
    confidence 90%
  2. Foghorn Faces Securities Probe After Lilly Partnership Collapse

    Pomerantz LLP is investigating whether Foghorn Therapeutics and its executives engaged in securities fraud following the collapse of a cancer drug development partnership with Eli Lilly and Company. The Watertown, Massachusetts biotech firm eliminated roughly 40 percent of its workforce, reducing staff to about 65 employees, after Phase 1 clinical data for the partnered drug FHD-909 failed to show required efficacy. Eli Lilly terminated the collaboration and dropped the selective SMARCA2 degrader program. Foghorn stock plunged over 30 percent, pushing the company's market capitalization below its cash holdings.

    Why it matters

    The collapse of the Eli Lilly collaboration stripped Foghorn of a major development partner and triggered a sharp market selloff. Biotech firms heavily rely on partnerships to fund expensive clinical trials, and pipeline failures often lead to immediate restructuring. Foghorn is now attempting to redirect its remaining resources toward proprietary assets to sustain operations into the second half of 2029.

    What is confirmed

    • Foghorn Therapeutics announced it will not advance its FHD-909 and SMARCA2 degrader programs and ended its collaboration with Eli Lilly.
    • Foghorn cut its workforce by 40 percent, reducing staff to about 65 employees.
    • Foghorn stock dropped over 30 percent following the announcement.
    • Foghorn's market capitalization fell below its cash reserves.

    Still unconfirmed

    • Pomerantz LLP is investigating whether Foghorn and its executives engaged in securities fraud or other unlawful practices.

    What to watch next

    • Developments regarding the Pomerantz LLP investor investigation into Foghorn Therapeutics
    • Updates on Foghorn's progress with proprietary pipeline assets including EP300 and CBP degraders
    Sources used for this update (4)
    1. www.biospace.com โ€” BioCryst ends all internal discovery efforts - BioSpace
    2. pluang.com โ€” Foghorn Therapeutics faces securities fraud pro... | Pluang
    3. www.coinmeta.com โ€” Investor Notice: Pomerantz Law Firm Investigating Foghorn ...
    4. insights.citeline.com โ€” Stock Watch: Foghorn And Sanofi Get The Marketโ€™s Verdict
    confidence 100%
  3. Foghorn Therapeutics Cuts 40 Percent of Staff After Lilly Split

    Foghorn Therapeutics is eliminating roughly 40 percent of its workforce, reducing staff to about 65 employees, following the collapse of a cancer drug development partnership with Eli Lilly and Company. The Watertown, Massachusetts biotech firm saw its stock plunge after Phase 1 clinical data for the partnered drug FHD-909 failed to show the efficacy required to advance into expansion phases. Eli Lilly terminated the multi-year collaboration, which also dropped its selective SMARCA2 degrader program. Foghorn is now pivoting its remaining resources toward proprietary pipeline assets, including preclinical EP300 and CBP degraders and an oral immunology program, to extend its cash runway into the second half of 2029.

    Why it matters

    The dissolution of the collaboration underscores the strict efficacy hurdles major pharmaceutical companies apply during early clinical evaluations in oncology. Foghorn spent millions under the agreement before clinical results ended the joint development efforts. Meanwhile, the sharp stock decline has triggered an investor investigation by Pomerantz Law Firm.

    What is confirmed

    • Foghorn Therapeutics is reducing its workforce by roughly 40 percent.
    • Eli Lilly terminated the cancer drug development partnership after a Phase 1 data review.
    • The Phase 1 clinical data for FHD-909 did not show the efficacy needed to enter the expansion phase.
    • The partnership dropped its selective SMARCA2 degrader program.
    • Foghorn is reprioritizing resources toward remaining proprietary portfolio programs, including preclinical EP300 and CBP degraders and an oral immunology program.

    Still unconfirmed

    • Pomerantz Law Firm is investigating claims on behalf of Foghorn Therapeutics investors.
    • Foghorn blew through $300 million of Eli Lilly's cash.

    What to watch next

    • Developments from the Pomerantz Law Firm investor investigation
    • Updates on Foghorn's preclinical EP300 and CBP degraders and oral immunology program
    Sources used for this update (5)
    1. www.cafepharma.com โ€” layoffs | Cafepharma
    2. eliteedgeenterprise.com โ€” Foghorn's 40% Layoffs: Biotech's Future?
    3. biotechmorning.com โ€” Foghorn Blew Through $300M of Lilly's Cash and Has Nothing to ...
    4. www.accessnewswire.com โ€” INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On ...
    5. news.qq.com โ€” Biotech้ญ้€€่ดง๏ผŒ็ดงๆ€ฅ่ฃๅ‘˜40%_่…พ่ฎฏๆ–ฐ้—ป
    confidence 100%
  4. Foghorn Cuts 40% of Staff After Eli Lilly Ends Partnership

    Foghorn Therapeutics is eliminating roughly 40% of its workforce following the collapse of its cancer drug development partnership with Eli Lilly and Company. The termination stems from a Phase 1 clinical data review for the drug FHD-909, also known as LY4050784. Both companies opted against advancing the program into the clinical development expansion phase after evaluating dose-escalation results. The partnership also dropped its selective SMARCA2 degrader program. Consequently, the Watertown, Massachusetts biotech is reprioritizing resources toward its remaining proprietary portfolio programs, which include preclinical EP300 and CBP degraders as well as an oral immunology program.

    Why it matters

    The strategic retreat highlights the high failure rate in early-stage oncology trials and the vulnerability of smaller biotech firms reliant on major pharma alliances. Founded by Flagship Pioneering to target the chromatin regulatory system, Foghorn now faces a significantly narrowed pipeline following the complete termination of collaboration activities with Lilly and its Loxo Oncology subsidiary. Wedbush downgraded Foghorn stock from outperform to neutral in response to the setback, indicating that the previous investment thesis no longer applies.

    What is confirmed

    • Foghorn Therapeutics is cutting about 40% of its staff after Eli Lilly and Foghorn dropped their SMARCA2 program in October 2026.
    • Foghorn and Eli Lilly decided not to advance the Phase 1 dose-escalation trial of FHD-909 into the clinical development expansion phase.
    • The collaboration will not advance the selective SMARCA2 degrader program, and the companies do not anticipate further collaboration activities.

    What to watch next

    • Updates on the progress of Foghorn's preclinical EP300 and CBP degraders
    • Developments regarding Foghorn's oral immunology program
    • Further stock performance and analyst adjustments following the downgrade by Wedbush
    Sources used for this update (5)
    1. www.thepharmaletter.com โ€” Foghorn Therapeutics | The Pharma Letter | The Pharmaletter
    2. flcube.com โ€” Foghorn Therapeutics and Lilly Discontinue FHDโ€‘909 and ...
    3. www.biospace.com โ€” Layoffs - BioSpace
    4. www.cafepharma.com โ€” Foghorn Therapeutics is cutting 40% of its workforce after ...
    5. www.biospace.com โ€” Massachusetts - BioSpace
    confidence 100%
  5. Foghorn Cuts 40% of Staff After Eli Lilly Cancer Partnership Ends

    Foghorn Therapeutics is reducing its workforce by 40% after the collapse of its cancer drug development partnership with Eli Lilly. The termination occurred because the cancer drug failed to meet efficacy benchmarks required for further testing. As a result, Wedbush downgraded Foghorn stock from outperform to neutral, noting that its previous bullish investment thesis no longer applies. This decision adds Foghorn to the list of global biopharma companies executing workforce reductions and strategic restructuring in October 2026 following pipeline setbacks.

    Why it matters

    The cancellation of the Eli Lilly collaboration forces Foghorn to restructure its operations and drastically downsize personnel. This setback highlights the high failure rate in early-stage oncology trials, where failing to meet efficacy thresholds can instantly invalidate major corporate partnerships and trigger severe market sell-offs. Companies dependent on collaborative funding must frequently pivot operations when lead candidates miss development milestones.

    What is confirmed

    • Foghorn Therapeutics is cutting 40% of its workforce following the end of its cancer drug collaboration with Eli Lilly.
    • The partnership ended because the cancer drug failed efficacy benchmarks required for further testing.
    • Wedbush downgraded Foghorn stock to Neutral from Outperform after the partnership ended.

    Still unconfirmed

    • Global biopharma layoffs in October 2026 also include workforce cuts and shutdowns at Adecto Pharmaceuticals and Aviceda Therapeutics.

    What to watch next

    • Further stock performance and market valuation shifts for Foghorn following the Wedbush downgrade.
    • Additional announcements regarding Foghorn's remaining pipeline assets and cash preservation strategies.
    Sources used for this update (4)
    1. theclinicaltimes.com โ€” Lilly ends Foghorn cancer drug partnership as biotech cuts 40 ...
    2. stockhub.kr โ€” Foghorn Cuts 40% of Workforce on Discontinuation of Cancer ...
    3. www.guidechem.com โ€” Global Biopharma Layoffs October 2026
    4. finance.yahoo.com โ€” FHTX Stock Extends Sell-Off After Lilly Collaboration Ends ...
    confidence 100%
  6. Foghorn Lays Off 40% of Staff as Eli Lilly Cancer Partnership Fails

    Foghorn Therapeutics is cutting 40% of its workforce, reducing staff to approximately 65 employees, after its cancer drug development collaboration with Eli Lilly collapsed. The partnership termination follows disappointing phase 1 dose-escalation data for FHD-909, also known as LY4050784, which failed to show sufficient efficacy to advance into an expansion phase. Additionally, the companies decided to scrap work on a related selective SMARCA2 degrader and chose not to extend their 2021 partnership. Foghorn stated that this restructuring and pipeline reprioritization will extend its cash runway into the second half of 2029.

    Why it matters

    The partnership between Foghorn Therapeutics and Eli Lilly began in 2021 to develop and commercialize oncology products centering on experimental SMARCA2 inhibitors. Following the failure of the trial data to meet expectations, TD Cowen downgraded Foghorn stock rating to Hold, and shares dropped amid trader focus on the company's remaining cash runway and charts. Foghorn now plans to refocus entirely on its proprietary portfolio programs.

    What is confirmed

    • Foghorn Therapeutics is laying off 40% of its workforce, leaving roughly 65 employees.
    • The collaboration between Foghorn and Eli Lilly ended after experimental cancer drug FHD-909 failed to show enough benefit in an early-stage phase 1 trial.
    • The companies are discontinuing work on both FHD-909, also called LY4050784, and a related selective SMARCA2 degrader.
    • TD Cowen cut Foghorn Therapeutics stock rating to Hold following the trial halt.
    • Foghorn stated the restructuring and pipeline reprioritization will extend its cash runway into the second half of 2029.

    What to watch next

    • Performance and clinical progress of Foghorn's remaining proprietary portfolio programs
    • Future updates on Foghorn's cash runway and financial health following the restructuring
    Sources used for this update (11)
    1. Fierce Biotech โ€” Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
    2. GlobeNewswire โ€” Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
    3. Barron's โ€” Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
    4. StocksToTrade โ€” FHTX Stock Slides As Traders Focus On Cash Runway And Charts
    5. Investing.com โ€” Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt
    6. www.biotech-now.co.uk โ€” Foghorn lays off 40% of employees as Lilly cancer collab ...
    7. www.biospace.com โ€” Foghorn lays off 40% of staff after Lilly collaboration ends
    8. theclinicaltimes.com โ€” Foghorn cuts 40% of workforce after Lilly collaboration ends
    9. finance.yahoo.com โ€” Foghorn to cut 40% of workforce after scrapping Lilly ...
    10. finance.yahoo.com โ€” Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal
    11. www.talk.bio โ€” Foghorn cuts 40% of staff after ending Lilly cancer programs
    confidence 100%
๐Ÿ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community